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Background
In 2006 the Canadian Global Health Research Initiative
launched, a CAD$ 3 million program designed to
strengthen the capacity for clinical trials of HIV vaccines
and other prevention technologies in Africa. Three teams
comprised of both African and Canadian HIV researchers
received two-year HIV/AIDS Prevention Trials Capacity
Building grants.
Methods
The three teams are using diverse but complementary
capacity building approaches with a mix of African-Cana-
dian and African-African research partnerships. In West
Africa, a Benin-Canada partnership is strengthening
capacity for clinical trials by: 1) training African investiga-
tors; 2) supporting the creation of the national Ethics
Committee for health research in Benin; and 3) support-
ing the creation of a HIV/STI Prevention Research Unit
within the Faculty of Health Sciences in Benin. A second
Africa-Canada team created and supported the Canada-
Africa Prevention Trials (CAPT) network which facilitates
north-south and south-south research partnerships in this
domain. The third team used the grant to build the African
Development of AIDS Prevention Trial (ADAPT) capacity
program. This program is strengthening the capacities of
local health systems to design, conduct, and use the evi-
dence from large-scale AIDS prevention trials in southern
Africa.
Results
These three projects are helping to build African capacity
to undertake HIV/AIDS clinical trials in Africa by: 1) com-
bining capacity building strategies both at the individual
institutional levels and 2) strengthening a range of skills
and knowledge that includes epidemiology, community
and stakeholder engagement, research management,
research ethics and grant writing.
Conclusion
These projects have created an important foundation that
is strengthening individual and institutional capacities
and helping African HIV investigators gain more auton-
omy, initiate and conduct research projects and obtain
grants. However, capacity building needs longer-term
funding to stimulate real advancements in the field of HIV
prevention. The early results of this program persuaded
funders to offer a new program with longer term grants.
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